Abalos Therapeutics is a biotech company that has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells.
Abalos Therapeutics' objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating a strong anti-tumor immune response.
Abalos Therapeutics was founded in 2019 by Karl Lang & Philipp Lang. The company is based in Essen, Germany.
Abalos’ goal is to capture the potent immune activation and highly specific tumor tropism of the arenavirus to propel a differentiated immuno-oncology approach towards clinical evaluation.
Abalos, through viral replication within cancer cells, its arenavirus-based drug candidates are designed to awake precise immune responses and activate all relevant immune cell types against primary tumors and metastases.
Abalos Therapeutics has raised €12M "Series A" at their launching event on Oct 15, 2019. It's investors include Boehringer Ingelheim Venture Fund (BIVF) and Gruenderfonds Ruhr, NRW.BANK and High-Tech Gruenderfonds (HTGF).